Check 35,000+ stocks against 26 valuation models and 37 quality factors

Exelixis Inc (EXEL) fair value: what the stock is really worth

We calculate from audited financials what Exelixis Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN US30161Q1040

Broad data Sep 18, 2026

Exelixis Inc

EXEL · US

Strongly undervaluedStrong Fair Value upside with high Quality.

✓Fair value $106.20 · Strongly undervalued (+82%)

✓Quality 94/100

✓Healthy Growth (revenue 5y +18.6 %/yr)

✓Highly profitable · 35.1% net margin (TTM)

✓Low debt · generates free cash flow

✓Ranks above peers (10/14)

✓Wide moat 93/100

!Insider activity 30/100

!The models disagree: range $53.29 to $211.01

26 models, one by oneBear $53.29 to bull $211.01 Growth analysisrevenue history, year by year Quality 94/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Exelixis Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 18, 2026.

How to read this chart

60‑month range $14.96 – $59.13 · fair‑value band $53.29 – $211.01 · the $58.36 price screens below the $106.20 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 18, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Stock analysis

Exelixis Inc (EXEL) currently trades at $58.36, while our model-based Fair Value estimate is $106.20, implying the stock looks roughly 45.0% undervalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of $107.58 per share, and 15 of the 24 models we run sit above the $58.36 price.

Bear case: the Economic Profit group reads lowest at $33.90, and 9 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: $53.29 (bear) to $211.01 (bull), the price of $58.36 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 94/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Exelixis Inc reported revenue of $2.3B in FY2025 versus $1.4B in FY2021, a compound +12.8%/yr. Reported net income was $783M in FY2025, compounding +35.7%/yr from FY2021.

Key figures

Market cap $16.4B · P/E ratio 19.4 · P/S ratio 6.54 · EPS (TTM) $3.01 · Net margin 33.7% · Return on equity 41.0% · Return on assets (EBIT) 14.9% · Operating margin 41.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 61 out of 100 (medium confidence).

What moves the price

The share trades near its 52-week high and 73% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 82%, EXEL screens cheaper than that median.

Fair Value models

Bear $53.29 Fair Value $106.20 Bull $211.01

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($2.18 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $58.41 $90.83 $194.09 75

EPV $28.91 $33.41 $37.36 74

Growth DCF $55.05 $100.79 $193.24 74

All 24 models by family

DCF Models

FCF DCF $58.41 $90.83 $194.09 75

Owner Earnings $50.07 $111.54 $240.61 70

5Y Revenue Exit $33.03 $51.82 $90.82 70

5Y EBITDA Exit $45.78 $77.60 $139.93 72

5Y P/E Exit $56.15 $122.73 $213.41 67

10Y Revenue Exit $40.08 $76.50 $96.76 67

10Y EBITDA Exit $50.26 $103.95 $195.73 65

10Y P/E Exit $57.82 $126.26 $238.62 60

Earnings-Based

Graham-Dodd $21.17 $147.64 $207.20 63

Lynch FV $58.71 $83.88 $109.04 61

PEG = 1.0 $58.71 $83.88 $109.04 57

EPV $28.91 $33.41 $37.36 74

Multiples

P/E Multiple $51.37 $68.49 $85.62 63

P/S Multiple $24.23 $32.31 $40.38 58

P/B Multiple $29.02 $38.69 $48.37 55

EV/EBIT $46.11 $60.86 $75.61 66

EV/EBITDA $39.52 $52.07 $64.62 67

EV/Revenue $21.26 $29.56 $37.87 54

Asset-Based

NCAV (Graham) $4.30 $5.76 $8.60 54

Growth DCF

Growth DCF $55.05 $100.79 $193.24 74

Rev-Margin DCF $33.71 $59.08 $107.62 69

Economic Profit

Residual Income $23.49 $33.90 $354.21 64

ROIC Compounder $35.71 $50.26 $70.00 71

Growth Earnings

Growth-Adj P/E $75.31 $107.58 $139.86 67

Open the full fair value analysis →

Notify me when EXEL reaches fair value

Put EXEL on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 94/100

Of which business quality 90 · Market factors (momentum, volatility) 80

Profitability 92

Margins and returns on capital today

Quality Growth 76

Are margins and returns improving?

Cashflow 86

Earnings quality: real cash, not paper profit

Fin. Strength 91

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 76

Calm price path (market factor)

Momentum 76

Price trend over the last 3–12 months (market factor)

52W Momentum 91

Distance to the 52-week high (market factor)

Net Issuance 100

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+7.0%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+12.9%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+18.6%

Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+29.3%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.

+32.8%

Earnings growth per share plus dividend.

Earnings per share, growth per year+32.8%

Dividend (yield on the price)0.0%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 38%

Growth Forecast

Little optimism in the price

The price assumes less growth than the company has delivered so far and less than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+3.5%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+11.0%

Yearly sales growth analysts expect, extended to five years.

Forecast 2026 (sales)+12.1%

Forecast 2027 (sales)+12.7%

Projected 2028 (sales)+11.4%

Projected 2029 (sales)+10.0%

Projected 2030 (sales)+8.7%

Watch EXEL, get fair value alerts →

Compare Exelixis Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 653 stocks

Beats the industry median on 10/14 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 94 · Top 25%

Fair Value upside −13% · Above median

Profitability

Return on equity (TTM) 41% · Top 25%

Return on assets 22% · Top 25%

Net margin (TTM) 35% · Top 25%

Operating margin (TTM) 41% · Top 25%

Growth and dividend

Revenue growth 10% · Above median

Balance sheet

Debt / equity 0.01× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 19.4× · Cheaper than median

P/B 6.46× · Priciest 25%

P/S (TTM) 5.88× · Pricier than median

P/FCF 16.5× · Pricier than median

EV/EBITDA 13.7× · Cheaper than median

PEG 2.27× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 0

FUTURE (revenue growth)50 · sector 0

PAST (return on equity)100 · sector 0

HEALTH (low debt)100 · sector 97

DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	$514.63	$566.09	+10%
Regeneron Pharmaceuticals, Inc REGN	$774.11	$1,241	+60%
argenx SE ARGX	$984.69	$917.18	−7%
BeOne Medicines AG 688235	¥247.30	¥124.62	−50%
Samsung Biologics Co 207940	1,396,000 KRW	1,535,600 KRW	+10%
CSL Limited CSL	A$174.41	A$191.85	+10%
Alnylam Pharmaceuticals, Inc ALNY	$238.27	$211.88	−11%
Royalty Pharma plc RPRX	$58.47	$24.22	−59%
Celltrion, Inc 068270	180,300 KRW	74,519 KRW	−59%
BioNTech SE BNTX	$96.69	$62.63	−35%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Exelixis Inc · Fair Value
$106.20 +45%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/EXEL" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Exelixis Inc · Fair Value</span><br><b style="font-size:20px">$106.20</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+45%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Exelixis Inc Fair Value". https://www.fairvalue-calculator.com/stock/EXEL

Frequently asked questions

Is Exelixis Inc (EXEL) overvalued or undervalued?

As of Sep 18, 2026, our model estimates a fair value of $106.20 versus a price of $58.36, about +82% upside (undervalued).

What is the fair value of EXEL?

Our model-based fair value for Exelixis Inc is $106.20 (as of Sep 18, 2026), built from audited fundamentals. The current price: $58.36.

What is the quality score of EXEL?

Exelixis Inc has a Quality Score of 94/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Exelixis Inc (EXEL)?

Our model-based price target is the fair value of $106.20 (as of Sep 18, 2026) from 24 valuation models. Cautious scenario $53.29, optimistic scenario $211.01. It is a calculation from audited fundamentals, not an analyst target.

What is the Exelixis Inc stock forecast for 2026?

Our models put fair value at $106.20, about +82% upside versus a price of $58.36 (undervalued). Cautious scenario $53.29, optimistic scenario $211.01. The calculation is refreshed regularly with new filings.

What is the revenue of Exelixis Inc (EXEL)?

Exelixis Inc reported trailing-twelve-month revenue of about $2.4B (latest available figure, as of Sep 18, 2026).

What growth is priced into Exelixis Inc (EXEL)?

For today's price to be fair in a discounted-cash-flow model, Exelixis Inc would have to grow free cash flow by +3.5 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.6 % per year. As of Sep 18, 2026.

What discount rate (WACC) does the fair value of EXEL use?

Our models discount Exelixis Inc at 8.1 %: a base by market capitalisation (large), damped by beta 0.42, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Exelixis Inc that is +3.5 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.

How much growth has Exelixis Inc (EXEL) delivered so far?

Over the past 5 years revenue at Exelixis Inc grew +18.6 % a year. The price currently implies +3.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Exelixis Inc (EXEL) growing?

The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Exelixis Inc (+3.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Exelixis Inc (EXEL)?

The free-cash-flow yield on the price is 5.13 %: that much free cash flow Exelixis Inc produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Exelixis Inc (EXEL)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Exelixis Inc it is $106.20 per share (as of Sep 18, 2026), against a price of $58.36. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Exelixis Inc stock overvalued or undervalued in 2026?

As of Sep 18, 2026, EXEL trades below its calculated fair value: price $58.36, fair value $106.20, a gap of about +82% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of EXEL?

No. The price is what the market pays today ($58.36); the fair value is what the company's own numbers justify ($106.20). For Exelixis Inc the two are $47.84 per share apart. That gap is exactly why we show both numbers side by side.

How much is Exelixis Inc worth?

The market values Exelixis Inc at about $16.4B (market capitalisation, as of Sep 18, 2026). Per share that is $58.36; our models calculate a fair value of $106.20 per share.

What do the bullish and bearish scenarios say about EXEL?

Our models span a range for Exelixis Inc: cautious scenario $53.29, base $106.20, optimistic $211.01 per share (as of Sep 18, 2026, price $58.36). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of EXEL?

Exelixis Inc trades at a price-to-earnings ratio of 19.4 (as of Sep 18, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $106.20 is built from several models across several years. Other multiples: PEG 2.3, P/B 6.5, P/S 5.9, EV/EBITDA 13.7.

What is the PEG ratio of EXEL?

The PEG ratio of Exelixis Inc is 2.27 (P/E divided by earnings growth, as of Sep 18, 2026). That is above 1, so the growth is already paid for in the price.

How solid is the balance sheet of Exelixis Inc (EXEL)?

Balance-sheet figures for Exelixis Inc (as of Sep 18, 2026): return on equity 41.0%, debt of 0.01 per unit of equity. They feed the Quality Score of 94/100, which measures business quality independently of the share price.

How far is EXEL from its 52-week high?

Exelixis Inc trades at $58.36, about 10% below its 52-week high of $52.96 and 73% above the low of $33.76 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $106.20 is for.

Which stocks are comparable to Exelixis Inc?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Exelixis Inc stock attractive at the current price?

The data as of Sep 18, 2026: price $58.36, calculated fair value $106.20 (+82%), Quality Score 94/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of EXEL calculated?

We run Exelixis Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $106.20, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 16.1 % above its aggregate fair value. Exelixis Inc currently trades 82 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Exelixis Inc (EXEL)?

The closing price on Sep 18, 2026 was $58.36. Our model-based fair value is $106.20, about +82% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Exelixis Inc right now?

The rarer combination: high quality (94/100) AND below fair value. That earns a closer look rather than a quick verdict. The model range is unusually wide ($53.29 to $211.01). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of Exelixis Inc

How large is the market capitalisation of Exelixis Inc (EXEL)?

The market capitalisation of Exelixis Inc is $16.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Exelixis Inc (EXEL)?

The price-to-sales ratio of Exelixis Inc is 6.54 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Exelixis Inc (EXEL)?

Earnings per share at Exelixis Inc are $3.01 (price ÷ EPS = P/E 19.4). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Exelixis Inc (EXEL)?

The net margin of Exelixis Inc is 33.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Exelixis Inc (EXEL)?

The return on equity (ROE) of Exelixis Inc is 41.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Exelixis Inc (EXEL)?

On an EBIT basis the return on assets of Exelixis Inc is 14.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Exelixis Inc (EXEL)?

The operating margin of Exelixis Inc is 41.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Exelixis Inc (EXEL)?

Revenue at Exelixis Inc is growing +10.0% versus a year earlier (3y avg +12.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Exelixis Inc (EXEL)?

Earnings per share at Exelixis Inc are growing +43.6% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Exelixis Inc (EXEL) hold?

Exelixis Inc holds more cash than debt, $309M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Exelixis Inc in the live analysis

One click puts Exelixis Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.